NCT03579316View on ClinicalTrials.gov

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 7, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
DRUG

Adavosertib

Given PO

DRUG

Olaparib

Given PO

DRUG

Ceralasertib

Given PO

Trial Locations (2)

77030

M D Anderson Cancer Center, Houston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER